Interferon Beta-1A
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Interferon beta-1a: From Multiple Sclerosis to Jeune Syndrome Situs Inversus
One-Sentence Summary
Interferon beta-1a is a recombinant cytokine widely established as a disease-modifying therapy for relapsing-remitting multiple sclerosis (RRMS), exerting its effects through immunomodulation to reduce relapse frequency and slow disease progression. The TxGNN model predicts it may be effective for Jeune Syndrome Situs Inversus (rank 1, score 97.47%), however no clinical trials and no publications currently support this specific indication — this is a pure AI model prediction at Evidence Level L5.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Multiple sclerosis (relapsing-remitting); original indications not recorded in this Evidence Pack |
| Predicted New Indication | Jeune Syndrome Situs Inversus |
| TxGNN Prediction Score | 97.47% |
| Evidence Level | L5 |
| Taiwan Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacological knowledge, Interferon beta-1a is a recombinant form of the endogenous cytokine IFN-β, primarily approved for relapsing-remitting multiple sclerosis. Its known biological actions include suppression of pro-inflammatory T-cell activity, reduction of cytokine-driven inflammation, inhibition of leukocyte trafficking across the blood–brain barrier, and upregulation of anti-inflammatory mediators — all targeting immune-mediated neuroinflammation.
Jeune Syndrome Situs Inversus (asphyxiating thoracic dystrophy with situs inversus) is a rare autosomal-recessive ciliopathy caused by loss-of-function mutations in genes encoding intraflagellar transport (IFT) complex components, most commonly DYNC2H1. The disease mechanism involves structural defects of primary cilia, leading to skeletal dysplasia, narrow thorax, and organ laterality reversal. This is a fundamentally developmental and structural disorder with no known immune-mediated component.
There is no established pharmacological pathway by which IFN-β-1a could repair ciliary architecture, rescue IFT gene function, or correct organ situs. The high TxGNN prediction score (97.47%) most likely reflects over-representation of rare-disease nodes within the knowledge graph — rare diseases tend to have high inter-connectivity — rather than a genuine drug–disease pharmacological relationship. This prediction should be regarded as a knowledge-graph artifact, not a credible repurposing hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Interferon beta-1a is currently not marketed in Taiwan. No marketing authorizations are on record.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| — | — | — | No authorizations found |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Jeune Syndrome Situs Inversus is a genetic ciliopathy driven by IFT complex dysfunction, with no immunological disease mechanism; IFN-β-1a has no plausible pathway to address ciliary structural defects, IFT gene mutations, or organ laterality reversal. All 10 top-ranked TxGNN predictions for this drug involve either structural chromosomal anomalies, developmental syndromes, or congenital malformations — none of which are mechanistically linked to IFN-β immunomodulation — suggesting a systematic model artefact rather than actionable repurposing signals.
To proceed, the following is needed:
- Basic science evidence (in vitro or animal models) demonstrating any effect of IFN-β signalling on IFT complex function or ciliogenesis
- Identification of any proposed biological mechanism linking type I interferon pathways to ciliopathy rescue
- Expert curation to determine whether any lower-ranked TxGNN predictions for Interferon beta-1a carry stronger mechanistic and clinical rationale
- TFDA prescribing information (SmPC) to complete the safety profile before any clinical consideration
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.